Phase I study of temozolomide in paediatric patients with advanced cancer. United Kingdom Children's Cancer Study Group.

A phase I study of temozolomide administered orally once a day, on 5 consecutive days, between 500 and 1200 mg m(-2) per 28-day cycle was performed. Children were stratified according to prior craniospinal irradiation or nitrosourea therapy. Sixteen of 20 patients who had not received prior craniosp...

Descripción completa

Detalles Bibliográficos
Autores principales: Estlin, E. J., Lashford, L., Ablett, S., Price, L., Gowing, R., Gholkar, A., Kohler, J., Lewis, I. J., Morland, B., Pinkerton, C. R., Stevens, M. C., Mott, M., Stevens, R., Newell, D. R., Walker, D., Dicks-Mireaux, C., McDowell, H., Reidenberg, P., Statkevich, P., Marco, A., Batra, V., Dugan, M., Pearson, A. D.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group|1 1998
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2063055/
https://www.ncbi.nlm.nih.gov/pubmed/9744506

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2063055/
https://www.ncbi.nlm.nih.gov/pubmed/9744506

Ejemplares similares